Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Nouvelles avancées sur les cellules souches du cancer. L’essentiel du Congrès Sunrise 2019.

Charafe-Jauffret E.

Bull Cancer. 2020 Jan;107(1):140-141. doi: 10.1016/j.bulcan.2020.01.005. Epub 2020 Jan 27. French. No abstract available.

PMID:
32000970
2.

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J, Josselin E, Macario M, Castellano R, Léonard-Stumpf C, Bal A, Gros A, Lossy S, Kharrat M, Collette Y, Bertucci F, Birnbaum D, Douik H, Bidaut G, Charafe-Jauffret E, Ginestier C.

EMBO Mol Med. 2019 Oct;11(10):e9930. doi: 10.15252/emmm.201809930. Epub 2019 Sep 2.

3.

Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking.

Bidan N, Bailleul-Dubois J, Duval J, Winter M, Denoulet M, Hannebicque K, El-Sayed IY, Ginestier C, Forissier V, Charafe-Jauffret E, Macario M, Matsunaga YT, Meignan S, Anquez F, Julien S, Bonnefond A, Derhourhi M, Le Bourhis X, Lagadec C.

Proteomics. 2019 Nov;19(21-22):e1800454. doi: 10.1002/pmic.201800454. Epub 2019 Sep 8.

PMID:
31430054
4.

[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].

Maran-Gonzalez A, Franchet C, Duprez-Paumier R, Antoine M, Barlier C, Becette V, Berghian A, Blanc-Fournier C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Fleury C, Garbar C, Ghnassia JP, Haudebourg J, MacGrogan G, Mathieu MC, Michenet P, Penault-Llorca F, Poulet B, Robin Y, Roger P, Russ E, Treilleux I, Valent A, Verriele V, Vincent-Salomon A, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2019 Dec;39(6):383-398. doi: 10.1016/j.annpat.2019.04.004. Epub 2019 Jun 27. French.

PMID:
31257035
5.

CD95/Fas and metastatic disease: What does not kill you makes you stronger.

Guégan JP, Ginestier C, Charafe-Jauffret E, Ducret T, Quignard JF, Vacher P, Legembre P.

Semin Cancer Biol. 2019 Jun 6. pii: S1044-579X(19)30129-4. doi: 10.1016/j.semcancer.2019.06.004. [Epub ahead of print] Review.

6.

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer.

Sabatier R, Charafe-Jauffret E, Pierga JY, Curé H, Lambaudie E, Genre D, Houvenaeghel G, Viens P, Ginestier C, Bertucci F, Sfumato P, Extra JM, Gonçalves A.

J Clin Med. 2019 May 6;8(5). pii: E612. doi: 10.3390/jcm8050612.

7.

Publisher Correction: PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling.

Nawrotek A, Benabdi S, Niyomchon S, Kryszke MH, Ginestier C, Cañeque T, Tepshi L, Mariani A, St Onge RP, Giaever G, Nislow C, Charafe-Jauffret E, Rodriguez R, Zeghouf M, Cherfils J.

Nat Chem Biol. 2019 May;15(5):549. doi: 10.1038/s41589-019-0255-0.

PMID:
30833779
8.

PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling.

Nawrotek A, Benabdi S, Niyomchon S, Kryszke MH, Ginestier C, Cañeque T, Tepshi L, Mariani A, St Onge RP, Giaever G, Nislow C, Charafe-Jauffret E, Rodriguez R, Zeghouf M, Cherfils J.

Nat Chem Biol. 2019 Apr;15(4):358-366. doi: 10.1038/s41589-019-0228-3. Epub 2019 Feb 11. Erratum in: Nat Chem Biol. 2019 Mar 4;:.

PMID:
30742123
9.

The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling.

Lopez Almeida L, Sebbagh M, Bertucci F, Finetti P, Wicinski J, Marchetto S, Castellano R, Josselin E, Charafe-Jauffret E, Ginestier C, Borg JP, Santoni MJ.

Stem Cell Reports. 2018 Nov 13;11(5):1040-1050. doi: 10.1016/j.stemcr.2018.09.008. Epub 2018 Oct 18.

10.

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.

Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L.

Oncotarget. 2018 Sep 18;9(73):33762-33777. doi: 10.18632/oncotarget.26031. eCollection 2018 Sep 18.

11.

Inflammatory breast cancer: The pathologists' perspective.

Cserni G, Charafe-Jauffret E, van Diest PJ.

Eur J Surg Oncol. 2018 Aug;44(8):1128-1134. doi: 10.1016/j.ejso.2018.04.001. Epub 2018 Apr 18. Review.

PMID:
29706301
12.

Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.

Doghri R, Manai M, Finetti P, Driss M, Agavnian E, Lopez M, Elghardallou M, Charafe-Jauffret E, Manai M, Chaffanet M, Birnbaum D, Mrad K, Bertucci F.

Int J Mol Sci. 2017 Dec 23;19(1). pii: E41. doi: 10.3390/ijms19010041.

13.

[Cancer stem cells and precision medicine].

Charafe-Jauffret E.

Bull Cancer. 2017 Dec;104(12):1088-1090. doi: 10.1016/j.bulcan.2017.10.021. Epub 2017 Nov 21. French. No abstract available.

PMID:
29169655
14.

[The concept of cancer stem cell].

Charafe-Jauffret E.

Bull Cancer. 2017 Dec;104(12):1056-1059. doi: 10.1016/j.bulcan.2017.10.020. Epub 2017 Nov 21. French. No abstract available.

PMID:
29169654
15.

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.

Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, Charafe-Jauffret E, Hervieu A, Extra JM, Viens P, Lokiec F, Boher JM, Gonçalves A.

Eur J Cancer. 2017 Nov;86:28-36. doi: 10.1016/j.ejca.2017.08.025. Epub 2017 Sep 23.

PMID:
28950146
16.

HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings.

Rioualen C, Da Costa Q, Chetrit B, Charafe-Jauffret E, Ginestier C, Bidaut G.

PLoS One. 2017 Sep 26;12(9):e0185400. doi: 10.1371/journal.pone.0185400. eCollection 2017.

17.

Salinomycin kills cancer stem cells by sequestering iron in lysosomes.

Mai TT, Hamaï A, Hienzsch A, Cañeque T, Müller S, Wicinski J, Cabaud O, Leroy C, David A, Acevedo V, Ryo A, Ginestier C, Birnbaum D, Charafe-Jauffret E, Codogno P, Mehrpour M, Rodriguez R.

Nat Chem. 2017 Oct;9(10):1025-1033. doi: 10.1038/nchem.2778. Epub 2017 May 16.

18.

Flick the cancer stem cells' switch to turn cancer off.

Ginestier C, Birnbaum D, Charafe-Jauffret E.

Mol Cell Oncol. 2017 Apr 28;4(4):e1319896. doi: 10.1080/23723556.2017.1319896. eCollection 2017.

19.

An iron hand over cancer stem cells.

Hamaï A, Cañeque T, Müller S, Mai TT, Hienzsch A, Ginestier C, Charafe-Jauffret E, Codogno P, Mehrpour M, Rodriguez R.

Autophagy. 2017 Aug 3;13(8):1465-1466. doi: 10.1080/15548627.2017.1327104. Epub 2017 Jun 14.

20.

A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability.

Morel AP, Ginestier C, Pommier RM, Cabaud O, Ruiz E, Wicinski J, Devouassoux-Shisheboran M, Combaret V, Finetti P, Chassot C, Pinatel C, Fauvet F, Saintigny P, Thomas E, Moyret-Lalle C, Lachuer J, Despras E, Jauffret JL, Bertucci F, Guitton J, Wierinckx A, Wang Q, Radosevic-Robin N, Penault-Llorca F, Cox DG, Hollande F, Ansieau S, Caramel J, Birnbaum D, Vigneron AM, Tissier A, Charafe-Jauffret E, Puisieux A.

Nat Med. 2017 May;23(5):568-578. doi: 10.1038/nm.4323. Epub 2017 Apr 10.

PMID:
28394329
21.

Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments.

Verdier-Pinard P, Salaun D, Bouguenina H, Shimada S, Pophillat M, Audebert S, Agavnian E, Coslet S, Charafe-Jauffret E, Tachibana T, Badache A.

Sci Rep. 2017 Mar 24;7:44976. doi: 10.1038/srep44976.

22.

miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling.

El Helou R, Pinna G, Cabaud O, Wicinski J, Bhajun R, Guyon L, Rioualen C, Finetti P, Gros A, Mari B, Barbry P, Bertucci F, Bidaut G, Harel-Bellan A, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Cell Rep. 2017 Feb 28;18(9):2256-2268. doi: 10.1016/j.celrep.2017.02.016.

23.

[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16. French.

PMID:
28214007
24.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2017 Mar;52(3):498. doi: 10.1038/bmt.2016.291. Epub 2017 Jan 16. No abstract available.

PMID:
28092355
25.

MARCKS protein overexpression in inflammatory breast cancer.

Manai M, Thomassin-Piana J, Gamoudi A, Finetti P, Lopez M, Eghozzi R, Ayadi S, Lamine OB, Manai M, Rahal K, Charafe-Jauffret E, Jacquemier J, Viens P, Birnbaum D, Boussen H, Chaffanet M, Bertucci F.

Oncotarget. 2017 Jan 24;8(4):6246-6257. doi: 10.18632/oncotarget.14057.

26.

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.

M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, Gonçalves A, Ginestier C, Charafe-Jauffret E, Birnbaum D, Olive D, Bertucci F, Lopez M.

Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.

27.

Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.

Boudin L, Gonçalves A, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Chabannon C.

J Cancer. 2016 Oct 23;7(14):2077-2084. eCollection 2016.

28.

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.

Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, Cabaud O, Finetti P, Brunelle S, Piana G, Tomassin-Piana J, Paciencia M, Lambaudie E, Popovici C, Sabatier R, Tarpin C, Provansal M, Extra JM, Eisinger F, Sobol H, Viens P, Lopez M, Ginestier C, Charafe-Jauffret E, Chaffanet M, Birnbaum D.

Oncotarget. 2016 Nov 29;7(48):79428-79441. doi: 10.18632/oncotarget.12714.

29.

Corrigendum to "Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation" [Eur J Cancer 57 (April 2016) 118-126].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Nov;67:223. doi: 10.1016/j.ejca.2016.09.002. Epub 2016 Sep 24. No abstract available.

PMID:
27680408
30.

Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.

Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, Charafe-Jauffret E, Pham K, Molck C, Rolland N, Bourgaux JF, Prudhomme M, Philippe C, Bravo S, Boyer JC, Canterel-Thouennon L, Taylor GR, Hsu A, Pascussi JM, Hollande F, Pannequin J.

Gut. 2017 Oct;66(10):1802-1810. doi: 10.1136/gutjnl-2016-311447. Epub 2016 Jul 25.

31.

Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis.

Sabatier R, Sabiani L, Zemmour C, Taix S, Chereau E, Gonçalves A, Jalaguier-Coudray A, Charafe-Jauffret E, Resbeut M, Extra JM, Viens P, Tallet A.

Breast. 2016 Jun;27:8-14. doi: 10.1016/j.breast.2015.12.003. Epub 2016 Mar 19.

PMID:
27212694
32.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2016 Aug;51(8):1082-6. doi: 10.1038/bmt.2016.82. Epub 2016 Apr 4. Erratum in: Bone Marrow Transplant. 2017 Mar;52(3):498.

PMID:
27042835
33.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY.

Lancet Oncol. 2016 May;17(5):600-11. doi: 10.1016/S1470-2045(16)00011-5. Epub 2016 Mar 28.

PMID:
27032301
34.

Comparative genomic analysis of primary tumors and metastases in breast cancer.

Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, Monneur A, Charafe-Jauffret E, Goncalves A, Viens P, Birnbaum D, Chaffanet M.

Oncotarget. 2016 May 10;7(19):27208-19. doi: 10.18632/oncotarget.8349.

35.

Breast cancer stem cells programs: enter the (non)-code.

Salvador MA, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Brief Funct Genomics. 2016 May;15(3):186-99. doi: 10.1093/bfgp/elw003. Epub 2016 Mar 8. Review.

PMID:
26955842
36.

Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Apr;57:118-26. doi: 10.1016/j.ejca.2016.01.005. Epub 2016 Feb 23. Erratum in: Eur J Cancer. 2016 Nov;67:223.

PMID:
26918737
37.

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.

Cserni G, Wells CA, Kaya H, Regitnig P, Sapino A, Floris G, Decker T, Foschini MP, van Diest PJ, Grabau D, Reiner A, DeGaetano J, Chmielik E, Cordoba A, Andreu X, Zolota V, Charafe-Jauffret E, Ryska A, Varga Z, Weingertner N, Bellocq JP, Liepniece-Karele I, Callagy G, Kulka J, Bürger H, Figueiredo P, Wesseling J, Amendoeira I, Faverly D, Quinn CM, Bianchi S.

Virchows Arch. 2016 Apr;468(4):473-81. doi: 10.1007/s00428-016-1909-x. Epub 2016 Jan 27.

PMID:
26818833
38.

Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer.

Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S, Sebbagh M, Lopez M, Brech A, Finetti P, Charafe-Jauffret E, Chaffanet M, Castellano R, Restouin A, Marchetto S, Collette Y, Gonçalvès A, Macara I, Birnbaum D, Kodjabachian L, Johansen T, Borg JP.

Nat Commun. 2016 Jan 12;7:10318. doi: 10.1038/ncomms10318.

39.

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.

Rahal S, Boher JM, Extra JM, Tarpin C, Charafe-Jauffret E, Lambaudie E, Sabatier R, Thomassin-Piana J, Tallet A, Resbeut M, Houvenaeghel G, Laborde L, Bertucci F, Viens P, Gonçalves A.

BMC Cancer. 2015 Oct 14;15:697. doi: 10.1186/s12885-015-1746-3.

40.

[Adenomyoepithelioma with dominant myoepithelial contingent of the breast: A case report and literature review].

Delteil C, Jalaguier Coudray A, Charafe Jauffret E, Thomassin Piana J.

Ann Pathol. 2015 Oct;35(5):449-53. doi: 10.1016/j.annpat.2015.05.006. Epub 2015 Sep 16. Review. French.

PMID:
26386768
41.

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.

Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3.

42.

Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.

Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Bonneterre J, Hernandez J, Bidard FC, Viens P.

Clin Cancer Res. 2015 Mar 15;21(6):1298-304. doi: 10.1158/1078-0432.CCR-14-1705. Epub 2014 Dec 23.

43.

[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].

MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, Treilleux I, Valent A, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):366-72. doi: 10.1016/j.annpat.2014.08.017. Epub 2014 Sep 26. French.

PMID:
25439989
44.

[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Poulet B, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):352-65. doi: 10.1016/j.annpat.2014.08.018. Epub 2014 Sep 26. French.

PMID:
25439988
45.

Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.

Gilabert M, Launay S, Ginestier C, Bertucci F, Audebert S, Pophillat M, Toiron Y, Baudelet E, Finetti P, Noguchi T, Sobol H, Birnbaum D, Borg JP, Charafe-Jauffret E, Gonçalves A.

PLoS One. 2014 Aug 21;9(8):e104302. doi: 10.1371/journal.pone.0104302. eCollection 2014.

46.

Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome.

El Helou R, Wicinski J, Guille A, Adélaïde J, Finetti P, Bertucci F, Chaffanet M, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Stem Cells. 2014 Nov;32(11):3031-6. doi: 10.1002/stem.1792.

47.

Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts.

Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D'Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS.

Stem Cell Reports. 2013 Dec 27;2(1):78-91. doi: 10.1016/j.stemcr.2013.11.009. eCollection 2014 Jan 14.

48.

Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.

Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, Raynaud S, Charafe-Jauffret E, Jacquemier J, Spicuglia S, de The H, Viens P, Bertucci F, Birnbaum D, Chaffanet M.

PLoS One. 2014 Jan 9;9(1):e81843. doi: 10.1371/journal.pone.0081843. eCollection 2014.

49.

Cytokeratin 7 as a predictive factor for response to concommitant radiochemotherapy for locally advanced cervical cancer: a preliminary study.

Lambaudie E, Chereau E, Pouget N, Thomassin J, Minsat M, Charafe-Jauffret E, Jacquemier J, Houvenaeghel G.

Anticancer Res. 2014 Jan;34(1):177-81.

PMID:
24403459
50.

ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri L, Harel-Bellan A, Chaffanet M, Viens P, Birnbaum D.

Cancer Res. 2013 Dec 15;73(24):7290-300. doi: 10.1158/0008-5472.CAN-12-4704. Epub 2013 Oct 18.

Supplemental Content

Loading ...
Support Center